We advised Dynamics Special Purpose Corp. on this transaction

Davis Polk advised Dynamics Special Purpose Corp. on its business combination with Senti Biosciences, Inc. The resulting combined company received gross proceeds of approximately $140 million from the cash held in trust after stockholder redemptions, the PIPE financing and recent financing by a leading strategic investor. The combined company, called Senti Biosciences, will commence trading on the Nasdaq Global Market under the symbol “SNTI” on June 9, 2022.

Dynamics Special Purpose Corp., a special purpose acquisition company (SPAC), was formed in May 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Dynamics Special Purpose Corp. focused its search in healthcare and the life sciences sectors. Senti Biosciences, Inc. is a biotechnology company that is developing next-generation cell and gene therapies using its proprietary gene circuit platform.

The Davis Polk corporate team includes partner Alan F. Denenberg, counsel W. Soren Kreider IV and associates Greg Travers, Elsie Cheang and Karen Yang. The tax team includes partner Patrick E. Sigmon and associate Benjamin Helfgott. Partner Adam Kaminsky and counsel Kevin A. Brown are providing executive compensation advice. Members of the Davis Polk team are based in the Northern California, New York and Washington DC offices.